Loading…
Loading…
Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 450,097 shares of the company's stock after buying an additional 358,540 shares during the quarter. Dimensional Fund Advisors
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,049,999 shares of the company's stock after purchasing an additional 2,839,266 shares during the quarter.
SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 926,557 shares of the company's stock, valued at approximately $3,864,000. Perspective Therapeutics comprises 3.1% of Ally
ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 687.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 749,335 shares of the company's stock after buying an additional 654,142 shares